Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
The University of Texas MD Anderson Cancer Center · Center for Systems Biology
Abstract
HER2-positive breast cancer accounts for 20-30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved patients' outcomes and paved the way for the beginning of advent of targeted approaches in breast cancer treatment. However, primary or acquired resistance to trastuzumab has been increasingly recognized as a major obstacle in the clinical management of this disease. In addition, in clinical practice, there are currently no conclusive biomarkers for patient response to trastuzumab. Therefore, understanding the molecular mechanism of trastuzumab and the development of resistance to this drug are of interest. Such…
Citation impact
- FWCI
- 10.34
- Percentile
- 100%
- References
- 43
Authors
2Topics & keywords
- Trastuzumab
- Breast cancer
- Medicine
- Oncology
- Action (physics)
- Internal medicine
- Cancer
- Bioinformatics
- No poverty